// App-Quantinova.ai

1731 : Overexpression of DCLK1 in pancreatic cancer activates KRAS/PI3K/MTOR pathway signaling and supports tumorigenesis, invasiveness, and stemness

Researchers

Presenter

  • Dongfeng Qu

Principal Investigators

  • Nathaniel Weygant

  • Randal May

  • William Berry

  • James Tomasek

  • Parthasarathy Chandrakesan

  • Michael Schlosser

  • Courtney Houchen

Medical Centers

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • COARE Biotechnology Inc., Oklahoma City, OK.

Locations

  • United States

Companies

  • COARE Biotechnology,

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Pancreas ductal adenocarcinoma

  • Pancreatic cancer

  • Solid malignancies

  • Microphthalmia, syndromic, 9

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • Solute Carrier Family 22 Member 3

  • Tripartite motif containing 27

  • PI3K/AKT

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Gemcitabine

  • Rapacan

  • XMD892

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved